In spite of targeting RAS itself, a dual FT and geranylgeranyltransferase‐1 inhibitor named FGTI‐2734 can inhibit the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (two G12D and two G12V) tumors.241. This evidence concerns the gene KRAS and pancreatic neoplasm.